ANN LEEN to Adoptive Transfer
This is a "connection" page, showing publications ANN LEEN has written about Adoptive Transfer.
Connection Strength
2.564
-
Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients. Curr Opin Infect Dis. 2018 08; 31(4):292-300.
Score: 0.547
-
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
Score: 0.384
-
T-cell therapy for viral infections. Hematology Am Soc Hematol Educ Program. 2013; 2013:342-7.
Score: 0.371
-
Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol. 2008 Oct; 143(2):169-79.
Score: 0.274
-
Improving T cell therapy for cancer. Annu Rev Immunol. 2007; 25:243-65.
Score: 0.245
-
T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15.
Score: 0.227
-
Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
Score: 0.101
-
Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
Score: 0.101
-
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2010 Mar; 10(3):337-51.
Score: 0.076
-
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
Score: 0.076
-
Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol. 2005 Jan; 128(2):135-44.
Score: 0.053
-
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27.
Score: 0.052
-
Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020 Jan 28; 4(2):387-397.
Score: 0.038
-
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2.
Score: 0.020